Organization | Shanghai Zerun Biotechnology Co.,Ltd

Shanghai Zerun Biotechnology Co.,Ltd Report issue

For profit Phase 2 Phase 3

Founded: Shanghai Germany (2003)

Status: Acquired by Walvax Biotechnology Co., Ltd. (2012)

Organization Overview

First Clinical Trial

2012

NCT01548118

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Shanghai Zerun Biotechnology Co.,Ltd | Yuxi Zerun Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

hpv 16/18 vaccine (Cervarix) (4 trials)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (2 trials)

Drugs in Phase 2 Trials (4)

202-cov (4 trials)

aluminum hydroxide (Gaviscon) (2 trials)

bnt162b2 (Comirnaty) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cervical Intraepithelial Neoplasia (Phase 3)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Papilloma (Phase 3)

Papillomavirus Infections (Phase 3)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 6